Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Leases: 2019-2025

Historic Current Leases for Theravance Biopharma (TBPH) over the last 7 years, with Sep 2025 value amounting to $10.9 million.

  • Theravance Biopharma's Current Leases rose 160.10% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 160.10%. This contributed to the annual value of $10.7 million for FY2024, which is 173.06% up from last year.
  • Theravance Biopharma's Current Leases amounted to $10.9 million in Q3 2025, which was up 0.17% from $10.9 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Current Leases high stood at $10.9 million for Q3 2025, and its period low was $503,000 during Q4 2021.
  • For the 3-year period, Theravance Biopharma's Current Leases averaged around $7.8 million, with its median value being $9.2 million (2023).
  • Its Current Leases has fluctuated over the past 5 years, first tumbled by 94.90% in 2021, then spiked by 1,303.61% in 2023.
  • Over the past 5 years, Theravance Biopharma's Current Leases (Quarterly) stood at $503,000 in 2021, then soared by 1,242.54% to $6.8 million in 2022, then plummeted by 41.91% to $3.9 million in 2023, then surged by 173.06% to $10.7 million in 2024, then skyrocketed by 160.10% to $10.9 million in 2025.
  • Its Current Leases stands at $10.9 million for Q3 2025, versus $10.9 million for Q2 2025 and $10.8 million for Q1 2025.